Early use of steroid‐sparing agents in the inactivation of moderate‐to‐severe active thyroid eye disease: a step‐down approach

Abstract

This study suggests that the initiation of an SSA, using methotrexate as first-line, with limited adjuvant IVMP is an effective and safe treatment for moderate-to-severely active TED, resulting in a significant reduction in both disease activity and total steroid load.